Novo Nordisk signed an agreement to develop oral insulin analogues using Merrion Pharmaceuticals’ Gastrointestinal Permeation Enhancement Technology (GIPET) in a deal valued at €45 M (US$58 M). Novo Nordisk is seeking alternative strategies for diabetes after abandoning its inhaled insulin product.